20,748 Shares in Collegium Pharmaceutical, Inc. $COLL Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, Holdings Channel.com reports. The firm purchased 20,748 shares of the specialty pharmaceutical company’s stock, valued at approximately $686,000.

A number of other institutional investors and hedge funds have also bought and sold shares of COLL. Rubric Capital Management LP lifted its position in shares of Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after purchasing an additional 29,876 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after purchasing an additional 18,160 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after purchasing an additional 3,891 shares during the period.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $34.82 on Tuesday. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a 1 year low of $29.19 and a 1 year high of $50.79. The stock’s 50 day simple moving average is $34.71 and its two-hundred day simple moving average is $38.64. The company has a market cap of $1.13 billion, a price-to-earnings ratio of 17.07 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.49 EPS. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.